ArticleWorld journal of urology2025
Efficacy, feasibility, and safety of aquablation after previous urolift treatment of lower urinary tract symptoms secondary to benign prostate hyperplasia: a retrospective cohort study.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Robot-Assisted Radical Prostatectomy After Rezūm: A Case Report and Literature Review.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe influence of a previous Urolift treatment on the outcomes of prostate Aquablation is still controversial. This retrospective cohort study aimed to evaluate the perioperative outcomes, efficacy, feasibility, and safety of Aquablation after previous Urolift treatment.
methodsThe charts of patients with benign prostate hyperplasia (BPH) complicated by storage and voiding symptoms, who were previously treated with Urolift followed by Aquablation between January 2022 and July 2024, were retrospectively reviewed and analyzed for changes in International Prostate Symptom Score (IPSS), maximum urinary flow rates (Qmax), and postvoid residual volume (PVR) from baseline (pre-Aquablation) to the mean of three months postoperatively. Day-case surgery was performed in 75% of the cases.
resultsThe study included 40 patients with a mean age of 68 (SD ± 8.91) years with moderately enlarged prostates (mean volume 81.56 mL, (SD ± 25.32), and median PSA 3.2 ng/dL). Five patients were presented initially with an indwelling Foley catheter, so their data were not included in the statistical analysis. After Aquablation, the mean IPSS improved from 24.7 (SD ± 7.63) at baseline to 9.8 (SD ± 2.55) (p < 0.0001), the mean Qmax increased from 9.6mL/sec (SD ± 5.76) at baseline to 20.8mL/sec (SD ± 6.28) (p < 0.0001), and the mean PVR decreased from 143mL (SD ± 104.89) at baseline to 36mL (SD ± 30.63 ) (p < 0.0001). The hospital stay for patients admitted ranged from 1 to 2 days. Moreover, there were no major intraoperative difficulties removing dislodged Urolift clips with a loop resectoscope at the end of the procedure, while non-dislodged clips were left in situ. None of the patients had postoperative bleeding that required hospital admission or blood transfusion following discharge.
conclusionBased on these results, prostate Aquablation appeared to be an effective, safe, feasible, and reliable surgical procedure for BPH patients who have had previous Urolift treatment. Further prospective and larger scale studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.